Fate Therapeutics, Inc. (FATE) is a publicly traded Healthcare sector company. As of August 25, 2026, FATE trades at $2.42 with a market cap of $279.18M and a P/E ratio of -2.30. FATE moved +5.15% today. Year to date, FATE is +148.32%; over the trailing twelve months it is +112.17%. Its 52-week range spans $0.66 to $3.23. Analyst consensus is buy with an average price target of $6.70. Rallies surfaces FATE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
7 analysts cover FATE: 0 strong buy, 4 buy, 3 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $6.70.
| Metric | Value |
|---|---|
| Price | $2.42 |
| Market Cap | $279.18M |
| P/E Ratio | -2.30 |
| EPS | $-1.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.23 |
| 52-Week Low | $0.66 |
| Volume | 1.24M |
| Avg Volume | 0 |
| Revenue (TTM) | $6.49M |
| Net Income | $-126.00M |
| Gross Margin | 0.00% |
7 analysts cover FATE: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.70.